Replicating Baker Brothers holdings, using 13F filings submitted quarterly by the life sciences hedge fund, has been an awesome strategy over the years. But by focusing on the smaller stocks owned by the fund, returns were even better. Baker Bros Advisors LP, with $17.33...
On Friday afternoon, CASI Pharma CEO He Wei-Wu filed a Form 4 disclosing the purchase of nearly $7.9M of CASI stock. The insider bought the shares in a public offering of 20M CASI shares at $1.90. President Larry Zhang also bought 20,153 shares in the secondary offering,...
Myriad Genetics co-founder Walter Gilbert PhD bought $150K of MYGN on Dec. 13 @ $25.60. Gilbert, who won the Nobel Prize for Chemistry in 1980, has a history of Form 4 filings at Myriad dating back to 2006. However, this is the insider's first open market purchase...
Protagonist Therapeutics insiders bought on Tuesday as their company's stock plummeted after preliminary data appeared to cast doubt on Protagonist's (PGTX) key drug. On Monday, the company presented an initial look at preliminary results from the TRANSCEND Ph2 open-label study of PTG-300 (hepcidin...
RA Capital Management leads the pack when it comes to health care stock selection. Since 2008, an equal-weight portfolio of the Boston-based hedge fund's top ten 13F positions would have averaged a 37.05% annual return. So, when RA Capital adds to a position, it pays to investigate....
RA Capital has outperformed all other healthcare hedge funds over the past decade, based on 13F holdings. In fact, RA's 30.88% annualized return of it's equal-weighted top 20 long portfolio led all other hedge funds over that period. So, when RA manager Peter Kolchinsky discloses portfolio changes,...
Solid Biosciences' private placement featured investments by an all star list of top biotech institutional investors. Cambridge-based Solid Biosciences (SLDB) trades at 1/3 of its January 2018 IPO value. But based on the A-list biotech investors buying shares in the company's July 26 $60...
Intra-Cellular Therapies FDA news release on Sept. 10 appeared positive. The FDA informed the company that it will not schedule an Advisory Committee meeting in connection with its review of the company’s new drug application (NDA) for Lumateperone for the treatment of schizophrenia. All good, moving ahead,...
Engine Capital filed a 13D targeting PDL BioPharm (PDLI) on Wednesday morning, disclosing a 5.28% stake in the Nevada-based healthcare stock. Engine also disclosed it sent a letter to PDLI's board saying the fund "invested in PDLI because of the significant intrinsic value attributable to...